PE-22-28 10mg (3ml Pen) – TREK-1 Ion Channel Research Peptide

PE-22-28 is a synthetic heptapeptide derived from spadin, a naturally occurring peptide fragment associated with sortilin processing. It has attracted scientific interest for its inhibitory activity at the TREK-1 potassium channel and its potential role in regulating neuronal excitability.

Unlike many neuropeptides investigated for indirect effects on neurotransmitter signalling, PE-22-28 has been studied in relation to a defined ion-channel target.

Preclinical studies have examined its activity in neuronal signalling, hippocampal neuroplasticity and experimental behavioural models associated with mood regulation.

PE-22-28 10mg is supplied in a 3ml pen format by Coridion Sciences for scientific and laboratory research.

What Is PE-22-28?

PE-22-28 is a seven-amino-acid peptide developed through research into spadin and the biological activity of shorter peptide fragments.

Spadin is a 17-amino-acid peptide derived from a region of the sortilin propeptide. It was identified through research examining the relationship between sortilin-related peptides and TREK-1 potassium channel activity.

Researchers subsequently investigated shorter spadin derivatives to identify sequences that retained inhibitory activity against TREK-1.

PE-22-28 emerged as one of the shorter active fragments identified during this work.

A 2017 study reported stronger TREK-1 inhibitory activity for PE-22-28 than the original spadin sequence in a laboratory cell model.

These findings established PE-22-28 as a subject of interest in potassium channel pharmacology and experimental neuroscience.

PE-22-28 and Cognitive Function Research

TREK-1 channels participate in the regulation of neuronal membrane potential and electrical excitability.

These processes are fundamental to communication between nerve cells and the functioning of neural networks.

Research involving PE-22-28 has investigated several areas:

• Ion channel regulation: Examining inhibition of TREK-1 potassium channel activity.
• Neuronal excitability: Investigating changes in electrical signalling associated with potassium channel modulation.
• Hippocampal neuroplasticity: Studying molecular and cellular markers associated with neural adaptation.
• Neurogenesis: Investigating the formation and development of neurons in experimental models.
• Mood-related behavioural research: Examining behavioural responses in rodent models used to investigate antidepressant-like activity.
• Peptide structure–activity relationships: Understanding how shortened spadin sequences influence biological activity.

Although these findings are relevant to neuroscience, they do not establish that PE-22-28 improves memory, concentration, mood or cognitive performance in humans.

Researchers exploring related compounds can browse our collection of peptides for cognitive and neurological research, featuring compounds investigated for neuronal signalling, neuroplasticity and experimental brain physiology.

How Does PE-22-28 Work?

TREK-1 Potassium Channel Inhibition

TREK-1 belongs to the two-pore-domain potassium channel family, commonly referred to as K2P channels.

These channels contribute to background potassium conductance and help regulate electrical activity in neurons.

PE-22-28 has been investigated as an inhibitor of TREK-1 activity.

Blocking these channels can influence neuronal excitability, providing a mechanistic basis for research into neural circuit function.

Spadin-Derived Peptide Activity

Spadin was identified as a peptide associated with sortilin processing and TREK-1 modulation.

Researchers investigated shortened spadin sequences to identify the structural regions necessary for channel inhibition.

PE-22-28 retains a seven-amino-acid sequence associated with this inhibitory activity.

Its shorter structure has also attracted interest in peptide degradation, stability and molecular optimisation.

Experimental Ion Channel Potency

In a 2017 study using human TREK-1 channels expressed in HEK cells, PE-22-28 demonstrated an inhibitory IC50 of approximately 0.12 nM, compared with approximately 40–60 nM for spadin.

This finding indicates greater inhibitory potency in that particular experimental system.

However, potency in a cell-based assay does not establish improved clinical effectiveness, brain exposure or safety in humans.

Neuronal Plasticity and Hippocampal Signalling

Research involving spadin and shortened analogues has examined cellular markers associated with hippocampal neurogenesis and synaptic activity.

Some animal studies have reported changes in neuronal proliferation and synaptic markers following experimental exposure.

These findings provide a basis for further investigating TREK-1-related neuronal signalling, but remain preclinical.

Scientific Research Applications

1. TREK-1 Receptor and Ion Channel Pharmacology

PE-22-28 is relevant to investigations examining the biological activity of TREK-1 potassium channels.

Laboratory research can use TREK-1-related experimental models to study membrane conductance and neuronal excitability.

2. Mood-Related Behavioural Models

Spadin and its shortened derivatives have been investigated in rodent behavioural models commonly used in antidepressant research.

Certain studies reported antidepressant-like behavioural effects.

However, these tests are experimental models and do not demonstrate that PE-22-28 is an effective treatment for depression in humans.

3. Hippocampal Neurogenesis

The hippocampus contributes to learning, memory and emotional processing.

Preclinical studies involving TREK-1 inhibition have investigated neurogenesis-related outcomes and synaptic markers within hippocampal tissue.

Further research is required to determine the relevance of these observations to human neurological function.

4. Peptide Stability and Molecular Design

Shortened spadin analogues were developed partly to investigate whether reduced peptide length and additional structural modifications could influence stability.

The available research provides useful insights into peptide design, although properties vary between different analogues.

Specific stability characteristics should be attributed only to the compounds actually examined.

5. Comparative Neuropeptide Research

PE-22-28 offers a distinct approach to neuroscience research compared with peptides investigated primarily through neurotrophic or neuroimmune mechanisms.

Its TREK-1 channel activity provides a defined target for studying neuronal signalling and structure–activity relationships.

PE-22-28 Compared with Related Cognitive Research Peptides

PE-22-28

A spadin-derived heptapeptide investigated for TREK-1 potassium channel inhibition, neuronal excitability and experimental mood-related behavioural responses.

Semax

A synthetic ACTH-derived peptide investigated for neurotrophic signalling, neurological responses and neuronal gene expression.

Selank

A tuftsin-related synthetic peptide associated with research into stress-related signalling, neurotransmitter systems and neuroimmune interactions.

P21

An experimental peptide associated with CNTF-derived neurotrophic research. Its molecular identity should be confirmed when comparing it with published studies involving P021.

These compounds differ in structure, proposed mechanisms and the maturity of their scientific evidence.

PE-22-28 10mg Product Specifications

• Product: PE-22-28
• Quantity: 10mg
• Format: 3ml pen
• Classification: Synthetic spadin-derived heptapeptide
• Peptide length: 7 amino acids
• Primary molecular target: TREK-1 potassium channel (KCNK2)
• Primary research focus: TREK-1 inhibition and neuronal excitability
• Additional research areas: Hippocampal neuroplasticity, behavioural neuroscience and peptide structure–activity relationships
• Evidence status: Preclinical, with limited independent replication and no established human clinical efficacy

Neuroscience Research at Coridion Sciences

Coridion Sciences provides specialist research peptides covering neurological signalling, cellular physiology and experimental biochemical research.

PE-22-28 forms part of the company’s cognitive research collection, alongside compounds associated with neurotrophic, neuroimmune and neuronal signalling pathways.

Its distinct TREK-1-related research profile makes it relevant to investigations examining potassium channel biology and neuropeptide pharmacology.

Research Use Only: PE-22-28 is an experimental compound intended exclusively for scientific and laboratory research. It is not approved for human consumption, depression treatment, cognitive enhancement or other therapeutic applications. Its safety, pharmacokinetics and clinical efficacy in humans have not been established.

PE-22-28 is a shortened spadin analogue reported to block the TREK-1 two-pore domain potassium channel. Research describes TREK-1 as a regulator of neuronal excitability whose inhibition produces effects on serotonergic signalling and hippocampal synaptogenesis. Studies in rodent models report changes in behavioural despair measures on a timescale shorter than that typically observed with monoamine-targeting compounds, alongside increases in markers of neurogenesis and synaptic density. The shortened sequence is reported to improve stability relative to full-length spadin.

A small, mechanistically specific preclinical literature concentrated in rodent models and produced by a limited number of research groups. No human data exist.

Ion channel research

Characterisation of TREK-1 blockade and effects on neuronal excitability.

Behavioural models

Rodent studies on despair and anxiety-related measures.

Neurogenesis

Work reporting increased hippocampal proliferation and synaptic markers.

Onset kinetics

Research comparing response timescale against monoamine-targeting comparators.

Evidence maturity

Entirely preclinical with limited independent replication.